| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/28/2003 | US6511987 Heterocyclic derivatives that bind to the benzodiazepine site of GABAA receptors for treatment of central nervous system disorders |
| 01/28/2003 | US6511986 Method of treating estrogen receptor positive carcinoma |
| 01/28/2003 | US6511985 HMG-CoA reductase inhibitor cerivastatin with fibrates such as fenofibrate or bezafibrate for the treatment of disorders of lipid metabolism |
| 01/28/2003 | US6511983 Pharmaceutical combination of antiviral agents |
| 01/28/2003 | US6511982 Synergistic mixture of acetaminophen and buspirone |
| 01/28/2003 | US6511981 Benzyl isooxazole and benzyl pyrazole derivatives as aldose reductase and cyclooxygenase-2 inhibitors |
| 01/28/2003 | US6511980 For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder |
| 01/28/2003 | US6511979 Methods for treating conditions modulated by lactosylceramide |
| 01/28/2003 | US6511978 Pyrrole derivatives useful for farnesyl transferase inhibitors and their preparations |
| 01/28/2003 | US6511977 For preventing or treating cardiac arrhythmia or atrial arrhythmia |
| 01/28/2003 | US6511976 Having antipsychotic, cardiovascular and gastrokinetic activity |
| 01/28/2003 | US6511973 Enzyme inhibitors of blood coaggulation factor X for use as anticoaggulants in the treatment of cardiovascular diseases associated with thromboses |
| 01/28/2003 | US6511972 Stable oral pharmaceutical formulations comprising amoxycillin trihydrate and potassium clavulanate |
| 01/28/2003 | US6511970 Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
| 01/28/2003 | US6511969 Method for reducing coronary artery reactivity |
| 01/28/2003 | US6511967 Administering to the subject a reporter complex including one or more receptor-specific reporter moieties linked to one or more reporter groups, such as magnetic particles, and detecting the reporter complex |
| 01/28/2003 | US6511966 Administering for therapy of mitochondria medited disease |
| 01/28/2003 | US6511964 Method for treating acute mountain sickness |
| 01/28/2003 | US6511960 Also cromolyn salts or esters; may be in combination with a corticosteroid; may also contain an antiphlogistic compound and hyaluronic acid |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511813 Identifying compound which inhibits peptide bond reaction of a complex formed by interaction of EFP, N-formyl methionyl-tRNA, 30S subunit, 50S subunit, an mRNA containing AUG sequence, initiation factors 1, 2, 3, and peptide bond donor |
| 01/28/2003 | US6511807 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 01/28/2003 | US6511801 HIV-1 group O strain gp160 env precursor protein comprising the amino acid sequence of SEQ ID NO:100 |
| 01/28/2003 | US6511800 Induction suppressor of a nitric oxide synthase or a cytokine; enzyme inhibitors |
| 01/28/2003 | US6511683 Enchinacea supplement and method of manufacture |
| 01/28/2003 | US6511681 Solubility and bioavailability of azole antifungal medicaments |
| 01/28/2003 | US6511680 Anti-inflammatory pharmaceutical formulations |
| 01/28/2003 | US6511679 Breath freshening comestible product and method of controlling breath malodor |
| 01/28/2003 | US6511678 Controlled release formulation of divalproex sodium |
| 01/28/2003 | US6511676 Forming cisplatin and ethanol buffered solution; combining with a negatively charged phosphatidyl glycerol lipid deriva-tive; able to reach primary tumors and their metastases after intravenous injection; breast and prostate cancer |
| 01/28/2003 | US6511675 Dietary supplements |
| 01/28/2003 | US6511673 Such as 2-methyl-3-isothiazolone with methyl and propyl p-hydroxybenzoates; effective, quick and long lasting; personal care products |
| 01/28/2003 | US6511670 (poly)thiaalkynoic compounds and pharmaceutical/cosmetic compositions comprised thereof |
| 01/28/2003 | US6511666 Purified antigenic complex comproised of multimeric protein complexes of arginine- and lysine-specific thiol endopepti-dases containing adhesion domains; raising antibody response against porphyromonas gingivalis |
| 01/28/2003 | US6511662 Treatment of cytomegalovirus using aminopeptidase N |
| 01/28/2003 | US6511660 Ophthalmic drug delivery formulations and method for preparing the same |
| 01/28/2003 | US6511659 Treatment of alopecia, cosmetics |
| 01/28/2003 | US6511653 Fluorocarbon polymer coating comprises the monomers tetrafluoroethylene, hexafluoropropylene, perfluoroalkoxyalkylene, and vinylidene fluoride; fluorocarbon propellant |
| 01/28/2003 | US6511652 Fluorocarbon polymer coating comprises the monomers tetrafluoroethylene, hexafluoropropylene, perfluoroalkoxyalkylene, and vinylidene fluoride; fluorocarbon propellant |
| 01/28/2003 | US6511648 Vitronectin receptor antagonist pharmaceuticals |
| 01/28/2003 | CA2417492A1 Preventives or remedies for obesity or fatty liver |
| 01/28/2003 | CA2307101C Pharmaceutical articles of manufacture comprising selective phosphodiesterase inhibitors for the treatment of sexual dysfunction |
| 01/28/2003 | CA2284910C Pharmaceutical combined preparations containing erythropoietin and iron preparations |
| 01/28/2003 | CA2273327C Stabilized ascorbyl compositions |
| 01/28/2003 | CA2245269C Solid pharmaceutical dispersions with enhanced bioavailability |
| 01/28/2003 | CA2196295C Stable vitamin a |
| 01/28/2003 | CA2148839C Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 01/28/2003 | CA2124375C Compounds containing a fused bicyclic ring and processes therefor |
| 01/28/2003 | CA2123124C Photosensitizers |
| 01/28/2003 | CA2108369C Method and composition for ameliorating the adverse effects of aging |
| 01/28/2003 | CA2094491C Alteration of rate and character of hair growth |
| 01/28/2003 | CA2094300C Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses |
| 01/28/2003 | CA2084799C Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones |
| 01/28/2003 | CA2083534C Indolopyrrolocarbazole derivatives |
| 01/28/2003 | CA2078869C Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use |
| 01/28/2003 | CA2032850C Crystalline magnesium valproate and a method for the preparation thereof |
| 01/28/2003 | CA2030962C Improvements relating to the administration of pharmaceutical agents |
| 01/27/2003 | WO2002010127A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/27/2003 | WO2002007713A2 Medicaments containing cilansetron for treating non-obstipated male ibs patients |
| 01/27/2003 | CA2417677A1 Medicaments containing cilansetron for treating non-obstipated male ibs patients |
| 01/27/2003 | CA2417427A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/27/2003 | CA2354250A1 Use of h1 histamine receptor antagonists for the prevention or attenuation of side effects associated with high doses of female hormones |
| 01/24/2003 | WO2002016308A1 Phenyl- and phenylalkyl-substituted ethanolamines and ethylenediamines |
| 01/24/2003 | WO2002010145A1 Urethane derivatives |
| 01/24/2003 | WO2002007735A1 Cardiac arrest fluid |
| 01/24/2003 | CA2417268A1 Urethane derivatives |
| 01/24/2003 | CA2394209A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/23/2003 | WO2003006893A2 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | WO2003006691A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 01/23/2003 | WO2003006662A1 Anti-neoplastic viral agents |
| 01/23/2003 | WO2003006628A2 Nad synthetase inhibitors and uses thereof |
| 01/23/2003 | WO2003006611A2 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE |
| 01/23/2003 | WO2003006608A2 Enhancement of transfection of dna into the liver |
| 01/23/2003 | WO2003006519A1 Polymers for oral use and compositions for oral use |
| 01/23/2003 | WO2003006509A2 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor |
| 01/23/2003 | WO2003006490A1 Bridged bicyclic serine protease inhibitors |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006477A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 01/23/2003 | WO2003006471A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| 01/23/2003 | WO2003006467A1 Novel anticonvulsant derivative salts |
| 01/23/2003 | WO2003006466A1 Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands |
| 01/23/2003 | WO2003006460A1 L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006458A1 Benzo [g] quinoline derivatives for treating glaucoma and myopia |
| 01/23/2003 | WO2003006457A1 Variolin derivatives and their use as antitumor agents |
| 01/23/2003 | WO2003006453A1 Aminediols for the treatment of alzheimer's disease |
| 01/23/2003 | WO2003006452A1 New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 01/23/2003 | WO2003006449A1 Method for the preparation of escitalopram |
| 01/23/2003 | WO2003006447A2 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | WO2003006441A1 Crystalline thiazine oxazolidinones |
| 01/23/2003 | WO2003006440A2 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound |
| 01/23/2003 | WO2003006438A1 Benzimidazole derivatives for treating microglia-activation associated diseases such as inflammatory, allergic, infectious or autoimmune diseases |
| 01/23/2003 | WO2003006436A1 Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides |
| 01/23/2003 | WO2003006430A1 Taxol enhancer compounds |
| 01/23/2003 | WO2003006428A1 Taxol enhancer compounds |
| 01/23/2003 | WO2003006427A1 Compounds that release nitric oxide at controlled rates upon photolysis |
| 01/23/2003 | WO2003006425A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006424A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006423A1 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| 01/23/2003 | WO2003006073A1 A composition and uses therefor for combating hangover |